0 items
Your cart is empty.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
99.2% On-Time Delivery
Tracked International Shipping
Refund Within 28 Days
Secure, Encrypted Checkout
$568.00
This product is available by prescription only
This product does not require a prescription
Out Of Stock
Each peptide batch is tested and verified to meet or exceed 98–99% purity (HPLC).
Store 2–8 °C (≤–20 °C long-term). RT exposure during transport acceptable. Protect from light.
The product is delivered in powdered (lyophilized) form and must be properly reconstituted prior to research use.
This 75mg vial provides an extended-capacity format for research purposes. Higher vial capacity is of most interest to long-duration research programs. Reduced reordering frequency supports workflow efficiency for professional labs. Lyophilized powder format ensures stability during long-term storage. Research facilities conducting extended studies value simplified peptide inventory management.
Quality Assurance: Novera’s extended-capacity Tirzepatide formulation maintains almost 99% purity through precision synthesis in USA GMP-certified facilities. Rigorous third-party testing protocols verify pharmaceutical-grade quality, ensuring professional researchers receive high-specification dual agonist peptides for institutional studies.
Tirzepatide is a leading-edge dual GIP/GLP-1 receptor agonist technology. Both incretin pathways are engaged by the peptide, allowing researchers to observe coordinated metabolic signaling. Dual-pathway research provides broader insight than single-receptor studies. Research worldwide continues to validate this two-pathway interaction model. Proven technology supports structured and repeatable institutional research planning.
Novera produces Tirzepatide in USA-certified GMP-grade facilities. Every vial is supplied with comprehensive COA documentation confirming peptide purity. This process ensures professional researchers receive pharmaceutical-grade peptides suitable for consistent institutional research outcomes.
Tirzepatide 75mg delivers an extended supply capacity for researchers conducting long-term dual-agonist investigations. For scientists and university research teams pursuing longevity-focused metabolic balance studies, sustained energy regulation research, and advanced GIP/GLP-1 pathway analysis, this large-format formulation is ideal. Collaborators running year-long or multi-phase studies benefit from the higher vial capacity, which supports consistent preparation and stable research conditions throughout in-vitro protocols.
For Research Use Only. This product is furnished for in-vitro studies only and is not for human consumption. Not approved by the FDA or EMA to prevent, treat, or cure any medical condition. Bodily introduction into humans or animals is strictly forbidden by law. Premium quality verified.
The 75mg concentration provides extended-capacity support for institutional research programs requiring high peptide availability across multi-phase investigations. Professional laboratories conducting long-duration or structured multi-arm studies benefit from consolidated supply and reduced resupply frequency.
Extended research timelines allow investigators to evaluate receptor signaling stability, pathway interaction consistency, and longitudinal biomarker modeling within controlled in-vitro systems. Higher-capacity formats support predictable procurement planning and streamlined research logistics across multi-site programs.
Institutional Quality: Approximately 99% purity verified through independent analytical testing ensures this extended-capacity formulation meets professional laboratory validation standards.
Tirzepatide is commonly studied for its dual agonist interaction with GIP and GLP-1 receptors in metabolic signaling research. Laboratory investigations may explore receptor binding dynamics, glucose pathway modeling, insulin signaling mechanisms, lipid interaction studies, and cardiovascular biomarker analysis within controlled experimental environments.
The 75mg format supports structured comparative research between dual-pathway peptides and single-receptor models. High-concentration availability enables uninterrupted execution of complex institutional research programs requiring consistent analytical material.
The extended-capacity vial supports multi-phase experimental design, concentration-ranging assays, and long-duration receptor interaction studies. Institutional research teams may evaluate pathway modulation patterns, signaling persistence models, and comparative dose-response frameworks based on study objectives.
Higher peptide availability allows laboratories to maintain workflow continuity across extended timelines without frequent supply fragmentation.
Working concentrations and exposure parameters are determined exclusively by laboratory-specific experimental frameworks. Structured progression models and concentration-ranging analyses are established according to institutional validation standards and research objectives.
The 75mg vial supports multi-month and multi-year investigative planning within regulated research environments.
Store lyophilized Tirzepatide at 2–8°C in temperature-controlled laboratory settings, protected from light exposure. Following reconstitution with validated laboratory-grade solvents, maintain refrigeration and adhere to sterile preparation procedures in certified research facilities.
Although cold-chain shipping is not required, refrigeration upon receipt is recommended to maintain structural stability. Laboratories must follow institutional handling protocols to preserve peptide integrity throughout extended research use.
Long-duration in-vitro investigations may span 52–104 weeks or longer to collect comprehensive longitudinal receptor interaction data. Research models may evaluate signaling dynamics, metabolic biomarker patterns, pathway stability, and comparative receptor activation metrics over time.
The 75mg concentration supports uninterrupted execution of multi-year institutional research programs, with volume procurement options available for coordinated laboratory networks.
Novera Research delivers high-quality research peptides developed under strict manufacturing and quality-control standards. Each product is carefully synthesized, tested, and handled to ensure consistency, reliability, and transparency for advanced research applications.
High-purity, research-grade peptide synthesis
Analytical testing to verify quality and composition
Consistent batch-to-batch performance
Batch identification on every vial for traceability
Stored and shipped under controlled conditions
Research-grade synthetic peptide analog formulated for experimental metabolic pathway research in controlled laboratory environments.
Research-grade synthetic dual-agonist peptide formulated in higher-quantity 15mg format for extended dual-receptor pathway studies and institutional peptide research in controlled laboratory environments.
Research-grade synthetic nonapeptide supplied in 5mg format for controlled in vitro laboratory investigation.
Research-grade synthetic pentadecapeptide designed for controlled laboratory peptide studies and institutional research programs.
A synthetic aromatic-cationic tetrapeptide studied for selective inner mitochondrial membrane localization, cardiolipin binding dynamics, and oxidative phosphorylation pathway marker activity in controlled in-vitro and preclinical models.
